Entero Therapeutics Inc. (ENTO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Entero Therapeutics Statistics
Share Statistics
Entero Therapeutics has 4.75M shares outstanding. The number of shares has increased by null% in one year.
Shares Outstanding | 4.75M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | n/a |
Shares Floating | - |
Failed to Deliver (FTD) Shares | 3.17K |
FTD / Avg. Volume | 1.51% |
Short Selling Information
The latest short interest is 94.02K, so 1.98% of the outstanding shares have been sold short.
Short Interest | 94.02K |
Short % of Shares Out | 1.98% |
Short % of Float | 2.02% |
Short Ratio (days to cover) | 0.12 |
Valuation Ratios
The PE ratio is -0.08 and the forward PE ratio is -0.41.
PE Ratio | -0.08 |
Forward PE | -0.41 |
PS Ratio | 0 |
Forward PS | 0.1 |
PB Ratio | 0.36 |
P/FCF Ratio | -0.1 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Entero Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.23.
Current Ratio | 1.58 |
Quick Ratio | 1.58 |
Debt / Equity | 0.23 |
Total Debt / Capitalization | 18.67 |
Cash Flow / Debt | -14.97 |
Interest Coverage | -702.08 |
Financial Efficiency
Return on equity (ROE) is -4.38% and return on capital (ROIC) is -356.02%.
Return on Equity (ROE) | -4.38% |
Return on Assets (ROA) | -2.29% |
Return on Capital (ROIC) | -356.02% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.75M |
Employee Count | 9 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -85.83% in the last 52 weeks. The beta is 1.22, so Entero Therapeutics 's price volatility has been higher than the market average.
Beta | 1.22 |
52-Week Price Change | -85.83% |
50-Day Moving Average | 0.58 |
200-Day Moving Average | 1.21 |
Relative Strength Index (RSI) | 44.62 |
Average Volume (20 Days) | 209.73K |
Income Statement
Revenue | n/a |
Gross Profit | -29.27K |
Operating Income | -15.77M |
Net Income | -15.79M |
EBITDA | -15.74M |
EBIT | n/a |
Earnings Per Share (EPS) | -47.88 |
Balance Sheet
The company has 3.71M in cash and 826.84K in debt, giving a net cash position of 2.88M.
Cash & Cash Equivalents | 3.71M |
Total Debt | 826.84K |
Net Cash | 2.88M |
Retained Earnings | -184.33M |
Total Assets | 85.82M |
Working Capital | 68.15M |
Cash Flow
In the last 12 months, operating cash flow was -12.38M and capital expenditures -500.00K, giving a free cash flow of -12.88M.
Operating Cash Flow | -12.38M |
Capital Expenditures | -500.00K |
Free Cash Flow | -12.88M |
FCF Per Share | -38.29 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ENTO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -9388.24% |
FCF Yield | -526.19% |
Analyst Forecast
Currently there are no analyst rating for ENTO.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:20.
Last Split Date | Dec 18, 2023 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -2.77 |
Piotroski F-Score | 1 |